INTUITIVE SURGICAL INC (IUI1.DE) Fundamental Analysis & Valuation

FRA:IUI1 • US46120E6023

420.35 EUR
+3.85 (+0.92%)
Last: Mar 9, 2026, 07:00 PM

This IUI1.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

7

IUI1 gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 65 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making IUI1 a very profitable company, without any liquidiy or solvency issues. IUI1 shows excellent growth, but is valued quite expensive already. These ratings could make IUI1 a good candidate for growth and quality investing.


Dividend Valuation Growth Profitability Health

9

1. IUI1.DE Profitability Analysis

1.1 Basic Checks

  • In the past year IUI1 was profitable.
  • In the past year IUI1 had a positive cash flow from operations.
  • In the past 5 years IUI1 has always been profitable.
  • IUI1 had a positive operating cash flow in each of the past 5 years.
IUI1.DE Yearly Net Income VS EBIT VS OCF VS FCFIUI1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

1.2 Ratios

  • IUI1's Return On Assets of 13.96% is amongst the best of the industry. IUI1 outperforms 95.38% of its industry peers.
  • With an excellent Return On Equity value of 16.02%, IUI1 belongs to the best of the industry, outperforming 87.69% of the companies in the same industry.
  • IUI1 has a better Return On Invested Capital (13.95%) than 89.23% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for IUI1 is in line with the industry average of 10.72%.
  • The last Return On Invested Capital (13.95%) for IUI1 is above the 3 year average (12.43%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 13.96%
ROE 16.02%
ROIC 13.95%
ROA(3y)12.67%
ROA(5y)12.15%
ROE(3y)14.56%
ROE(5y)13.99%
ROIC(3y)12.43%
ROIC(5y)12.44%
IUI1.DE Yearly ROA, ROE, ROICIUI1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15

1.3 Margins

  • IUI1 has a better Profit Margin (28.38%) than 100.00% of its industry peers.
  • IUI1's Profit Margin has improved in the last couple of years.
  • Looking at the Operating Margin, with a value of 29.35%, IUI1 belongs to the top of the industry, outperforming 96.92% of the companies in the same industry.
  • IUI1's Operating Margin has improved in the last couple of years.
  • With a decent Gross Margin value of 66.00%, IUI1 is doing good in the industry, outperforming 73.85% of the companies in the same industry.
  • IUI1's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 29.35%
PM (TTM) 28.38%
GM 66%
OM growth 3Y4.58%
OM growth 5Y3.73%
PM growth 3Y10.12%
PM growth 5Y3.12%
GM growth 3Y-0.72%
GM growth 5Y0.11%
IUI1.DE Yearly Profit, Operating, Gross MarginsIUI1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

9

2. IUI1.DE Health Analysis

2.1 Basic Checks

  • IUI1 has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • The number of shares outstanding for IUI1 has been reduced compared to 1 year ago.
  • Compared to 5 years ago, IUI1 has more shares outstanding
  • IUI1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IUI1.DE Yearly Shares OutstandingIUI1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
IUI1.DE Yearly Total Debt VS Total AssetsIUI1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B

2.2 Solvency

  • An Altman-Z score of 41.19 indicates that IUI1 is not in any danger for bankruptcy at the moment.
  • IUI1's Altman-Z score of 41.19 is amongst the best of the industry. IUI1 outperforms 100.00% of its industry peers.
  • IUI1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 41.19
ROIC/WACC1.41
WACC9.89%
IUI1.DE Yearly LT Debt VS Equity VS FCFIUI1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.3 Liquidity

  • A Current Ratio of 4.87 indicates that IUI1 has no problem at all paying its short term obligations.
  • The Current ratio of IUI1 (4.87) is better than 96.92% of its industry peers.
  • IUI1 has a Quick Ratio of 3.96. This indicates that IUI1 is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 3.96, IUI1 belongs to the top of the industry, outperforming 96.92% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.87
Quick Ratio 3.96
IUI1.DE Yearly Current Assets VS Current LiabilitesIUI1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

8

3. IUI1.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 21.83% over the past year.
  • IUI1 shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 21.42% yearly.
  • The Revenue has grown by 20.51% in the past year. This is a very strong growth!
  • IUI1 shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.22% yearly.
EPS 1Y (TTM)21.83%
EPS 3Y23.94%
EPS 5Y21.42%
EPS Q2Q%14.48%
Revenue 1Y (TTM)20.51%
Revenue growth 3Y17.39%
Revenue growth 5Y18.22%
Sales Q2Q%18.76%

3.2 Future

  • IUI1 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.58% yearly.
  • IUI1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.90% yearly.
EPS Next Y14.45%
EPS Next 2Y14.34%
EPS Next 3Y14.52%
EPS Next 5Y13.58%
Revenue Next Year15.88%
Revenue Next 2Y14.86%
Revenue Next 3Y14.57%
Revenue Next 5Y12.9%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
IUI1.DE Yearly Revenue VS EstimatesIUI1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B 15B 20B
IUI1.DE Yearly EPS VS EstimatesIUI1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15 20

1

4. IUI1.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 54.38, which means the current valuation is very expensive for IUI1.
  • Based on the Price/Earnings ratio, IUI1 is valued a bit more expensive than 61.54% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 26.45. IUI1 is valued rather expensively when compared to this.
  • IUI1 is valuated quite expensively with a Price/Forward Earnings ratio of 47.52.
  • Based on the Price/Forward Earnings ratio, IUI1 is valued a bit more expensive than the industry average as 69.23% of the companies are valued more cheaply.
  • When comparing the Price/Forward Earnings ratio of IUI1 to the average of the S&P500 Index (24.65), we can say IUI1 is valued expensively.
Industry RankSector Rank
PE 54.38
Fwd PE 47.52
IUI1.DE Price Earnings VS Forward Price EarningsIUI1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of IUI1 indicates a slightly more expensive valuation: IUI1 is more expensive than 67.69% of the companies listed in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of IUI1 indicates a slightly more expensive valuation: IUI1 is more expensive than 60.00% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 69.25
EV/EBITDA 45.11
IUI1.DE Per share dataIUI1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • IUI1 has an outstanding profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as IUI1's earnings are expected to grow with 14.52% in the coming years.
PEG (NY)3.76
PEG (5Y)2.54
EPS Next 2Y14.34%
EPS Next 3Y14.52%

0

5. IUI1.DE Dividend Analysis

5.1 Amount

  • No dividends for IUI1!.
Industry RankSector Rank
Dividend Yield 0%

IUI1.DE Fundamentals: All Metrics, Ratios and Statistics

INTUITIVE SURGICAL INC

FRA:IUI1 (3/9/2026, 7:00:00 PM)

420.35

+3.85 (+0.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)01-22
Earnings (Next)04-20
Inst Owners88.53%
Inst Owner ChangeN/A
Ins Owners0.45%
Ins Owner ChangeN/A
Market Cap149.28B
Revenue(TTM)10.06B
Net Income(TTM)2.86B
Analysts78.1
Price Target527.49 (25.49%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.28%
Min EPS beat(2)9.85%
Max EPS beat(2)18.71%
EPS beat(4)4
Avg EPS beat(4)10.81%
Min EPS beat(4)3.05%
Max EPS beat(4)18.71%
EPS beat(8)8
Avg EPS beat(8)11.52%
EPS beat(12)12
Avg EPS beat(12)8.73%
EPS beat(16)14
Avg EPS beat(16)6.39%
Revenue beat(2)2
Avg Revenue beat(2)2.19%
Min Revenue beat(2)2.17%
Max Revenue beat(2)2.22%
Revenue beat(4)4
Avg Revenue beat(4)1.83%
Min Revenue beat(4)1.09%
Max Revenue beat(4)2.22%
Revenue beat(8)5
Avg Revenue beat(8)1.43%
Revenue beat(12)7
Avg Revenue beat(12)0.96%
Revenue beat(16)9
Avg Revenue beat(16)0.46%
PT rev (1m)-1.16%
PT rev (3m)0.59%
EPS NQ rev (1m)-0.08%
EPS NQ rev (3m)0.27%
EPS NY rev (1m)0%
EPS NY rev (3m)3.07%
Revenue NQ rev (1m)-0.07%
Revenue NQ rev (3m)0.45%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)1.02%
Valuation
Industry RankSector Rank
PE 54.38
Fwd PE 47.52
P/S 17.14
P/FCF 69.25
P/OCF 56.92
P/B 9.68
P/tB 9.89
EV/EBITDA 45.11
EPS(TTM)7.73
EY1.84%
EPS(NY)8.85
Fwd EY2.1%
FCF(TTM)6.07
FCFY1.44%
OCF(TTM)7.39
OCFY1.76%
SpS24.53
BVpS43.44
TBVpS42.49
PEG (NY)3.76
PEG (5Y)2.54
Graham Number86.92
Profitability
Industry RankSector Rank
ROA 13.96%
ROE 16.02%
ROCE 16.01%
ROIC 13.95%
ROICexc 20.73%
ROICexgc 21.4%
OM 29.35%
PM (TTM) 28.38%
GM 66%
FCFM 24.75%
ROA(3y)12.67%
ROA(5y)12.15%
ROE(3y)14.56%
ROE(5y)13.99%
ROIC(3y)12.43%
ROIC(5y)12.44%
ROICexc(3y)18.4%
ROICexc(5y)18.81%
ROICexgc(3y)19.07%
ROICexgc(5y)19.65%
ROCE(3y)14.27%
ROCE(5y)14.28%
ROICexgc growth 3Y2.03%
ROICexgc growth 5Y0.92%
ROICexc growth 3Y2.86%
ROICexc growth 5Y2.05%
OM growth 3Y4.58%
OM growth 5Y3.73%
PM growth 3Y10.12%
PM growth 5Y3.12%
GM growth 3Y-0.72%
GM growth 5Y0.11%
F-Score8
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 79.72%
Cap/Sales 5.36%
Interest Coverage 250
Cash Conversion 83.46%
Profit Quality 87.21%
Current Ratio 4.87
Quick Ratio 3.96
Altman-Z 41.19
F-Score8
WACC9.89%
ROIC/WACC1.41
Cap/Depr(3y)178.7%
Cap/Depr(5y)155.64%
Cap/Sales(3y)11.2%
Cap/Sales(5y)9.67%
Profit Quality(3y)61.68%
Profit Quality(5y)71.87%
High Growth Momentum
Growth
EPS 1Y (TTM)21.83%
EPS 3Y23.94%
EPS 5Y21.42%
EPS Q2Q%14.48%
EPS Next Y14.45%
EPS Next 2Y14.34%
EPS Next 3Y14.52%
EPS Next 5Y13.58%
Revenue 1Y (TTM)20.51%
Revenue growth 3Y17.39%
Revenue growth 5Y18.22%
Sales Q2Q%18.76%
Revenue Next Year15.88%
Revenue Next 2Y14.86%
Revenue Next 3Y14.57%
Revenue Next 5Y12.9%
EBIT growth 1Y25.34%
EBIT growth 3Y22.76%
EBIT growth 5Y22.63%
EBIT Next Year35.56%
EBIT Next 3Y21.57%
EBIT Next 5Y17.26%
FCF growth 1Y91.03%
FCF growth 3Y37.49%
FCF growth 5Y16.85%
OCF growth 1Y25.49%
OCF growth 3Y26.68%
OCF growth 5Y15.34%

INTUITIVE SURGICAL INC / IUI1.DE FAQ

Can you provide the ChartMill fundamental rating for INTUITIVE SURGICAL INC?

ChartMill assigns a fundamental rating of 7 / 10 to IUI1.DE.


Can you provide the valuation status for INTUITIVE SURGICAL INC?

ChartMill assigns a valuation rating of 1 / 10 to INTUITIVE SURGICAL INC (IUI1.DE). This can be considered as Overvalued.


Can you provide the profitability details for INTUITIVE SURGICAL INC?

INTUITIVE SURGICAL INC (IUI1.DE) has a profitability rating of 9 / 10.


Can you provide the financial health for IUI1 stock?

The financial health rating of INTUITIVE SURGICAL INC (IUI1.DE) is 9 / 10.